Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177671 | SCV000229575 | benign | not specified | 2015-02-23 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000231585 | SCV000291331 | benign | Autosomal recessive polycystic kidney disease | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000177671 | SCV000315797 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000177671 | SCV000699861 | benign | not specified | 2019-07-18 | criteria provided, single submitter | clinical testing | Variant summary: PKHD1 c.3686G>C (p.Trp1229Ser) results in a non-conservative amino acid change located in the IPT domain (IPR002909) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0034 in 280922 control chromosomes, predominantly at a frequency of 0.033 within the African or African-American subpopulation in the gnomAD database, including 18 homozygotes. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 4 fold of the estimated maximal expected allele frequency for a pathogenic variant in PKHD1 causing Polycystic Kidney and Hepatic Disease phenotype (0.0071), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. The variant, c.3686G>C, has been reported in the literature in individuals affected with juvenile myoclonic epilepsy or Autosomal recessive polycystic kidney disease (Suzuki_2006, Melchionda_2016). These reports do not provide unequivocal conclusions about association of the variant with Polycystic Kidney and Hepatic Disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions from other clinical diagnostic laboratories (evaluation after 2014) classified the variant as benign (2x) and likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as benign. |
Counsyl | RCV000231585 | SCV000788695 | likely benign | Autosomal recessive polycystic kidney disease | 2017-01-06 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000231585 | SCV001325407 | benign | Autosomal recessive polycystic kidney disease | 2017-04-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. |
Gene |
RCV001706138 | SCV001897578 | benign | not provided | 2020-07-27 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 16876319, 27225849) |
Ce |
RCV001706138 | SCV004699639 | benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | PKHD1: BP4, BS1, BS2 |
Natera, |
RCV000231585 | SCV002080991 | benign | Autosomal recessive polycystic kidney disease | 2017-05-17 | no assertion criteria provided | clinical testing |